| Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts | Ben Fidler | 04/13/18 | National |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More | Frank Vinluan | 11/03/17 | National |
| Spero, Allena Nab $152M As Bio IPOs, With Insider Help, Continue Roll | Ben Fidler | 11/02/17 | Boston |
| Xconomy Q&A: An Update with Arcturus Therapeutics CEO Joseph Payne | Bruce V. Bigelow | 10/23/17 | San Diego |
| Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug | Ben Fidler | 09/20/17 | Boston |
| Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More | Alex Lash | 09/01/17 | National |
| GSK Hands Nerve Drug Back to Ionis as RNA Battle Heats Up | Ben Fidler | 08/11/17 | San Diego |
| Akcea Slashes IPO Price Ahead of Filing for Rare Disease Drug | Frank Vinluan | 07/14/17 | Boston |
| Regulus Dumps Two Drugs, AstraZeneca Sends Back Another, Shares Fall | Ben Fidler | 06/12/17 | San Diego |
| Ionis Touts Phase 3 Win, But Safety Worries Cloud Nerve Drug Study | Ben Fidler | 05/15/17 | San Diego |
| Ionis Pharma Spins Out Lipid Disorder Unit Akcea with Plans for IPO | Frank Vinluan | 03/27/17 | Boston |
| Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths | Ben Fidler | 02/01/17 | Boston |
| Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval | Ben Fidler | 01/24/17 | Boston |
| Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug | Ben Fidler | 01/06/17 | National |
| Ionis, Biogen Make History With FDA Nod for Spine Disease Drug | Ben Fidler | 12/23/16 | Boston |
| Bio Roundup: Trump’s Triumph, Election Fallout, CRISPR Arguments & More | Ben Fidler | 11/11/16 | National |
| Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA | Ben Fidler | 08/26/16 | National |
| Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More | Ben Fidler | 08/05/16 | National |
| Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing | Ben Fidler | 08/01/16 | Boston |
| Regulus Shares Crumble As FDA Halts Testing of Hepatitis C Drug | Ben Fidler | 06/27/16 | San Diego |
| Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More | Ben Fidler | 05/27/16 | National |
| East Coast Biotech Roundup: Harvard’s Haul, Patent Fights, Padlock & More | Ben Fidler | 03/24/16 | Boston |
